Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 11/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11890480 | 0.93 | DYRK1A (0.45) | DYRK1ADYRK1BHTTBUB1ALDH1A1 | |
| SCHEMBL10322550 | 0.89 | RAB9A (0.41) | DYRK1ADYRK1BBUB1ALDH1A1POLB | |
| SCHEMBL10322294 | 0.86 | BUB1 (0.39) | DYRK1ADYRK1BHTTBUB1ALDH1A1 | |
| SCHEMBL10322375 | 0.80 | BUB1 (0.41) | MAPK14BUB1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL10322224 | 0.80 | DYRK1A (0.59) | DYRK1ADYRK1BMAPK14ALDH1A1POLB | |
| SCHEMBL10321271 | 0.77 | DYRK1A (0.72) | DYRK1ADYRK1BMAPK14ALDH1A1 | |
| SCHEMBL10322440 | 0.73 | DYRK1A (0.61) | DYRK1ADYRK1BMAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL10322166 | 0.73 | BUB1 (0.38) | DYRK1ADYRK1BBUB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10318281 | 0.71 | DYRK1A (1.00) | DYRK1ADYRK1BMAPK14ALDH1A1 | |
| SCHEMBL10321365 | 0.71 | DYRK1A (0.80) | DYRK1ADYRK1BHTTMAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | DYRK1A 1366/4885DYRK1B 2109/4885HTT 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.